News | March 29, 2012

Resolute Stent Shows Good Safety Profile Out to Two Years

March 29, 2012 — In the second year of an ongoing trial, the Resolute zotarolimus-eluting stent (Medtronic) achieved a low rate of stent thrombosis, cardiac death, target vessel heart attack and target lesion revascularization years, according to research presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.

The Resolute U.S. trial reported similar results in year one, examining safety and efficacy outcomes for a zotarolimus-eluting stent that was approved by the U.S. Food and Drug Administration (FDA) in February. The stent includes a new biocompatible polymer that allows for an extended drug release across approximately six months, which has been hypothesized to better prevent restenosis (vessel renarrowing) while maintaining a low rate of stent thrombosis (blood clots).

For the study, 1,402 patients were enrolled at 116 centers in the United States between August 2008 and December 2009. The mean patient age was 64.1 years and 68.3 percent of patients were male; 34.4 percent had diabetes, the highest percentage included in any trials of the zotarolimus-eluting stent to date but a percentage that is characteristic of patients in the U.S. who receive angioplasty. During their angioplasty procedure, each patient received a zotarolimus-eluting stent ranging from 2.25 mm to 4 mm in either one or two lesions. Participants were then followed either with clinical follow-up (n=1242) or angiographic follow-up (n=160) to determine the rates of adverse events.

Specifically, the study’s primary endpoint was the rate of target lesion failure, a composite of cardiac death, target-vessel heart attack, and clinically driven target lesion revascularization by angioplasty or surgical methods. The secondary endpoints included the individual rates of cardiac death, clinically driven target lesion revascularization and definite plus probable stent thrombosis.

At the two-year follow-up point, the researchers obtained data from 1,359 of the enrolled participants. Of these, 7.3 percent experienced the primary endpoint of target lesion failure, while 3 percent experienced cardiac death, 1.9 percent experienced target-vessel heart attack and 4.3 percent experienced clinically driven target lesion revascularization; 0.2 percent of patients experienced definite or probable stent thrombosis.

The two-year results were similar to the one-year findings, which included a 4.7 percent rate of target lesion failure and a 0.1 percent of definite or probable stent thrombosis.

According to lead investigator Laura Mauri, M.D., M.Sc., an interventional cardiologist at Brigham & Women’s Hospital and associate professor of medicine at Harvard Medical School, diabetic patients— who generally are more likely to suffer from restenosis or stent thrombosis—did particularly well in the study, with a two-year rate of target lesion failure of 8.2 percent and no stent thrombosis events at two years.

“Within a study population where one-third of the patients were diabetic and 10.7 percent were treated in small vessels, the Resolute U.S. study’s two-year results showed the clinical endpoint of low target lesion failure was achieved with very low stent thrombosis risk,” said Mauri. “These results will greatly facilitate catheter-based treatment of a broader group of patients with symptomatic coronary artery disease.”

The study was funded by Medtronic. Mauri is a consultant to and receives institutional grant support from Medtronic.

For more information: www.acc.org

Related Content

A 3-D rendering created from the chest CT scan of a 41-year-old coronavirus patient in China showing ground-glass opacities in several areas of the lungs from the coronavirus pneumonia. This was from one of the first medical imaging studies published on COVID-19 in the journal Radiology. #coronavirus #COVID2019 #COVID19 #2019nCoV

A 3-D rendering created from the chest CT scan of a 41-year-old coronavirus patient in China showing ground-glass opacities in several areas of the lungs from the coronavirus pneumonia. This was from one of the first medical imaging studies published on COVID-19 in the journal Radiology. 

Feature | Cardiovascular Clinical Studies | February 20, 2020 | Dave Fornell, Editor
February 20, 2020 — The American College of Cardiology (ACC) released a
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Overlay Init